Evidence for peptidoglycan absorption in rats with experimental small bowel bacterial overgrowth.
Surgical creation of jejunal self-filling blind loops (SFBL) causes small bowel bacterial overgrowth which is associated with hepatobiliary inflammation in the susceptible Lewis and Wistar rat strains. Since hepatic injury occurs when small bowel anaerobic bacterial concentrations are increased 4 to 6 log10 units per ml and hepatic bacterial cultures are negative, we postulate that the inflammation is caused by absorption of phlogistic cell wall polymers originating from bacteria within the loop. To demonstrate absorption of bacterial cell wall polymers, we measured plasma and hepatic levels of immunoreactive peptidoglycan-polysaccharide (PG-PS) following intraluminal injection as well as anti-PG antibodies as an indirect measure of absorption and/or accumulation of endogenous PG. PG-PS purified from group A streptococci was detected in plasma by enzyme-linked immunosorbent assay after intraluminal injection; rats with SFBL showed significantly more uptake into plasma and the liver than sham-operated rats or SFBL rats which were treated with metronidazole (P less than 0.025). Total plasma immunoglobulin A (IgA), IgG, and IgM levels did not differ among sham-operated rats and those with self-emptying blind loops or SFBL, but plasma anti-PG IgA (P less than 0.05), IgG, and IgM (P less than 0.01) levels were increased in rats with SFBL. Metronidazole and tetracycline prevented the elevation of anti-PG antibody, but gentamicin and polymyxin B did not. Anti-lipid A, anti-soy protein, and anti-chow antibodies in plasma were not consistently increased in rats with SFBL indicating the lack of a generalized antibody response to luminal antigens. These data suggest that PG from normal flora bacteria is absorbed from the intestinal lumen and that mucosal injury and/or increased luminal concentrations of PG, such as those induced by small bowel bacterial overgrowth, lead to enhanced absorption of potentially inflammatory bacterial polymers.
Lichtman
S N
SN
Department of Pediatrics, University of North Carolina, Chapel Hill 27599-7220.
Keku
J
J
Schwab
J H
JH
Sartor
R B
RB
D000818:Animals; D000907:Antibodies, Bacterial / Q000032:analysis; D001419:Bacteria / Q000254:growth & development*; D007070:Immunoglobulin A / Q000032:analysis; D007408:Intestinal Absorption; D007421:Intestine, Small / Q000276:immunology / Q000382:microbiology*; D008198:Lymph Nodes / Q000276:immunology; D010457:Peptidoglycan / Q000276:immunology / Q000493:pharmacokinetics*; D011135:Polysaccharides, Bacterial / Q000276:immunology / Q000493:pharmacokinetics; D051381:Rats; D011917:Rats, Inbred Lew
D000907:Antibodies, Bacterial; D007070:Immunoglobulin A; D010457:Peptidoglycan; D011135:Polysaccharides, Bacterial